Detoxified Endotoxin Vaccine (J5dLPS/OMP) Protects Mice Against Lethal Respiratory Challenge with Francisella tularensis SchuS4

Vaccine

Volumn 28, Issue 16, 2010, Pages 2908-2915

  Gregory, Stephen H ^a,b   Chen, Wilbur H ^c   Mott, Stephanie ^a   Palardy, John E ^d   Parejo, Nicholas A ^d   Heninger, Sara ^e   Anderson, Christine A ^e   Artenstein, Andrew W ^b,d   Opal, Steven M ^b,d   Cross, Alan S ^c  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Lipopolysaccharide; Lungs; Tularemia

Indexed keywords

BACTERIAL VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DETOXIFIED ENDOTOXIN VACCINE; EPITOPE; GLYCOLIPID; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FRANCISELLA TULARENSIS; IMMUNITY; IMMUNIZATION; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY SYSTEM; TULAREMIA;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; BRONCHOALVEOLAR LAVAGE FLUID; COLONY COUNT, MICROBIAL; ENDOTOXINS; FEMALE; FRANCISELLA TULARENSIS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; LIVER; LUNG; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; SERUM; SURVIVAL ANALYSIS; TULAREMIA;

EID: 77949654791     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.067     Document Type: Article

References (50)

1. Dennis D.T., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Tularemia as a biological weapon: medical and public health management. JAMA 285 21 (2001) 2763-2773
2. Johansson A., Ibrahim A., Goransson I., Eriksson U., Gurycova D., Clarridge III J.E., et al. Evaluation of PCR-based methods for discrimination of Francisella species and subspecies and development of a specific PCR that distinguishes the two major subspecies of Francisella tularensis. J. Clin. Microbiol. 38 11 (2000) 4180-4185
3. Saslaw S., Eigelsbach H.T., Prior J.A., Wilson H.E., and Carhart S. Tularemia vaccine study. II: respiratory challenge. Arch. Int. Med. 107 (1961) 134-146
4. Oyston P.C., Sjostedt A., and Titball R.W. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2 12 (2004) 967-978
5. Eigelsbach H.T., and Downs C.M. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87 (1961) 415-425
6. Baron S.D., Singh R., and Metzger D.W. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect. Immun. 75 5 (2007) 2152-2162
7. Rawool D.B., Bitsaktsis C., Li Y., Gosselin D.R., Lin Y., Kurkure N.V., et al. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium. Francisella tularensis. J. Immunol. 180 8 (2008) 5548-5557
8. Eyles J.E., Hartley M.G., Laws T.R., Oyston P.C., Griffin K.F., and Titball R.W. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS). Microb. Pathog. 44 2 (2008) 164-168
9. Wayne C.J., and Oyston P.C. Vaccines against Francisella tularensis. Ann. N. Y. Acad. Sci. 1105 (2007) 325-350
10. Bakshi C.S., Malik M., Mahawar M., Kirimanjeswara G.S., Hazlett K.R., Palmer L.E., et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26 41 (2008) 5276-5288
11. Richard J.L., and Grimes D.E. Bioterrorism: class A agents and their potential presentations in immunocompromised patients. Clin. J. Oncol. Nurs. 12 2 (2008) 295-302
12. Fulop M., Manchee R., and Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13 13 (1995) 1220-1225
13. Fulop M., Mastroeni P., Green M., and Titball R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19 31 (2001) 4465-4472
14. Conlan J.W., Vinogradov E., Monteiro M.A., and Perry M.B. Mice intradermally-inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen. Microb. Pathog. 34 1 (2003) 39-45
15. Huntley J.F., Conley P.G., Rasko D.A., Hagman K.E., Apicella M.A., and Norgard M.V. Native outer membrane proteins protect mice against pulmonary challenge with virulent Type A Francisella tularensis. Infect. Immun. (2008)
16. Conlan J.W., Shen H., Webb A., and Perry M.B. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20 29-30 (2002) 3465-3471
17. Fulop M., Manchee R., and Titball R. Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol. Med. Microbiol. 13 3 (1996) 245-247
18. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 11 3 (1989) 440-451
19. + T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect. Immun. 62 (1994) 5603-5607
20. Drabick J.J., Narayanan R.B., Williams J.C., Leduc J.W., and Nacy C.A. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am. J. Med. Sci. 308 2 (1994) 83-87
21. Kirimanjeswara G.S., Golden J.M., Bakshi C.S., and Metzger D.W. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J. Immunol. 179 1 (2007) 532-539
22. Janovska S., Pavkova I., Hubalek M., Lenco J., Macela A., and Stulik J. Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS. Immunol. Lett. 108 2 (2007) 151-159
23. Cross A.S., Opal S.M., Palardy J.E., Drabick J.J., Warren H.S., Huber C., et al. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21 31 (2003) 4576-4587
24. Cross A.S., Opal S., Cook P., Drabick J., and Bhattacharjee A. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. Vaccine 22 7 (2004) 812-817
25. Opal S.M., Palardy J.E., Chen W.H., Parejo N.A., Bhattacharjee A.K., and Cross A.S. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms. J. Infect. Dis. 192 12 (2005) 2074-2080
26. Bhattacharjee A.K., Opal S.M., Taylor R., Naso R., Semenuk M., Zollinger W.D., et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J. Infect. Dis. 173 5 (1996) 1157-1163
27. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., and Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. Invest 63 5 (1979) 836-848
28. Cross A.S., Opal S.M., Warren H.S., Palardy J.E., Glaser K., Parejo N.A., et al. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J. Infect. Dis. 183 7 (2001) 1079-1086
29. Chen W.H., Kang T.J., Bhattacharjee A.K., and Cross A.S. Intranasal administration of a detoxified endotoxin vaccine protects mice against heterologous Gram-negative bacterial pneumonia. Innate. Immun. 14 5 (2008) 269-278
30. Gregory S.H., Mott S., Phung J., Lee J., Moise L., McMurry J.A., et al. Epitope-based vaccination against pneumonic tularemia. Vaccine 27 (2009) 5299-5306
31. Sebastian S., Pinkham J.T., Lynch J.G., Ross R.A., Reinap B., Blalock L.T., et al. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 27 4 (2009) 597-605
32. Kim J., Merry A.C., Nemzek J.A., Bolgos G.L., Siddiqui J., and Remick D.G. Eotaxin represents the principal eosinophil chemoattractant in a novel murine asthma model induced by house dust containing cockroach allergens. J. Immunol. 167 5 (2001) 2808-2815
33. Gregory S.H., Cousens L.P., van Rooijen N., Döpp E.A., Carlos T.M., and Wing E.J. Complemetary adhesion molecules promote neutrophil-Kupffer cell interaction and the elimination of bacteria taken up by the liver. J. Immunol. 168 (2002) 308-315
34. Bevanger L., Maeland J.A., and Kvan A.I. Comparative analysis of antibodies to Francisella tularensis antigens during the acute phase of tularemia and eight years later. Clin. Diagn. Lab Immunol. 1 2 (1994) 238-240
35. Twine S.M., Petit M.D., Shen H., Mykytczuk N.C., Kelly J.F., and Conlan J.W. Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines. Biochem. Biophys. Res. Commun. 346 3 (2006) 999-1008
36. Vinogradov E., Perry M.B., and Conlan J.W. Structural analysis of Francisella tularensis lipopolysaccharide. Eur. J. Biochem. 269 24 (2002) 6112-6118
37. Gunn J.S., and Ernst R.K. The structure and function of Francisella lipopolysaccharide. Ann. N. Y. Acad. Sci. 1105 (2007) 202-218
38. Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., and Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458 7242 (2009) 1191-1195
39. Kaisho T., and Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589 1 (2002) 1-13
40. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5 7 (2007) 505-517
41. Wetzler L.M. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine 21 Suppl 2 (2003) S55-S60
42. Hajjar A.M., Harvey M.D., Shaffer S.A., Goodlett D.R., Sjostedt A., Edebro H., et al. Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors. Infect. Immun. 74 12 (2006) 6730-6738
43. Thakran S., Li H., Lavine C.L., Miller M.A., Bina J.E., Bina X.R., et al. Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR) 2/TLR1 heterodimer. J. Biol. Chem. 283 7 (2008) 3751-3760
44. Malik M., Bakshi C.S., Sahay B., Shah A., Lotz S.A., and Sellati T.J. Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect. Immun. 74 6 (2006) 3657-3662
45. Chiavolini D., Weir S., Murphy J.R., and Wetzler L.M. Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia. Clin. Vaccine Immunol. 15 9 (2008) 1322-1329
46. Chen WH, Basu S, Bhattacharjee AK, Cross AS. Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors. Innate.Immun. 2009; (in press).
47. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199 (2004) 201-216
48. Shen H., Chen W., and Conlan J.W. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen. Vaccine 22 17-18 (2004) 2116-2121
49. Chen W., Shen H., Webb A., KuoLee R., and Conlan J.W. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21 25-26 (2003) 3690-3700
50. Chiavolini D., Alroy J., King C.A., Jorth P., Weir S., Madico G., et al. Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia. Infect. Immun. 76 2 (2008) 486-496